Aspire Biopharma Holdings heads into its May 19 earnings report with one of the most expensive borrow markets on Nasdaq — a signal that the lending side of the trade is under real strain.
The clearest indicator is the cost to borrow. At 240% annualised, borrowing shares of ASBP is punishingly expensive — up 25% in a week and near the highest levels seen in the past six weeks. That kind of premium signals sustained demand for short exposure in a name with a tiny lending pool. Availability has tightened sharply since early May, when most of the pool sat idle; the borrow market is now roughly 78% committed, compared to 100% fully exhausted through most of April and into early May. The ORTEX short score has climbed to 80.8 — its highest reading in the current data window — reflecting the convergence of elevated borrowing costs, tightening availability, and recent short interest momentum.
Short interest itself tells a more nuanced story. At just 0.1% of the free float, directional short positioning is negligible in aggregate. What the history reveals is violent volatility in the estimated short shares — spiking to over 2.5 million in early May before collapsing back to roughly 108,000 by May 14. That pattern points less to a structural bear thesis and more to short-term traders cycling aggressively in and out of the name, likely responding to the stock's own extreme price moves. The stock has fallen 84% in a single month to $5.61, even after recovering 1% on the week and briefly bouncing on individual sessions.
The price history around prior prints shows that ASBP can move sharply in either direction. The last three confirmed events produced a 13% one-day decline in November 2025, a 15% gain in August 2025, and a 16% jump in June 2025 — with the five-day reaction generally extending in the same direction as the initial move. The March 2026 result added a further 13% gain on the day, stretching to 24% over the following week. With a market cap now under $1 million and no available fundamental data to anchor valuation, the stock is trading on momentum and sentiment rather than earnings multiples.
The May 19 print will test whether there is any stabilising fundamental narrative to interrupt the month-long collapse — or whether the borrow market's continued pressure reflects something more durable about near-term supply and demand for the shares.
See the live data behind this article on ORTEX.
Open ASBP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
